CRB-913 is Corbus Pharmaceuticals's once-daily oral peripherally-restricted CB1 cannabinoid receptor inverse agonist developed for the treatment of obesity. The mechanism is designed as an orthogonal, non-incretin approach that would complement or serve as an alternative to the GLP-1 class for patients who do not respond adequately to weekly semaglutide or tirzepatide.
The drug is engineered to remain peripheral: preclinical studies in mice documented approximately 15-fold lower brain penetration than monlunabant (a comparable CB1 inverse agonist in clinical development at other sponsors). Peripheral restriction is the differentiation from Sanofi's Acomplia (rimonabant), which was approved for obesity in Europe in 2006 but withdrawn in 2008 after post-marketing surveillance identified elevated rates of anxiety, depression, and suicidal ideation. Corbus's design bet is that peripheral CB1 blockade preserves the metabolic effects (appetite suppression, insulin sensitivity, lipolysis) without the central nervous system side effects that ended rimonabant.
The Phase 1b CANYON-1 study enrolled 254 obese non-diabetic U.S. adults across 15 sites, testing once-daily doses of 20 mg, 40 mg, and 60 mg versus placebo over 12 weeks of treatment with a 4-week safety follow-up. On Monday September 14, 2026, Corbus reported positive CANYON-1 topline: mean weight loss of 5.0% at 60 mg (n=62), 3.3% at 40 mg (n=61), 2.8% at 20 mg (n=65), versus 0.0% on placebo (n=66), all p<0.0001. No plateau was observed at any dose. Gastrointestinal adverse events at 60 mg: nausea 22.6%, diarrhea 22.6%, constipation 4.8%, vomiting 1.6%. Discontinuation rates ranged 3.1-13.1% across doses (versus 6.9-20.7% for oral GLP-1s in cross-trial comparison). Psychiatric adverse events at 60 mg (the class-defining safety concern following the 2008 rimonabant withdrawal): depression 1.6%, anxiety 4.8%, irritability 9.7%, insomnia 0% — no serious psychiatric events or suicidality reported. CRBP shares closed up 12%. Corbus plans FDA engagement on the clinical development plan, a Phase 2 monotherapy trial initiation in H1 2027, and early evaluation of a GLP-1 combination approach. Full data will be presented at ObesityWeek 2026 in Washington DC (November 14-17). See [[corbus-pharmaceuticals]], [[rimonabant-history]], and [[monlunabant-comparator]] for adjacent threads.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced Monday September 14, 2026 positive topline results from the Phase 1b CANYON-1 trial evaluating CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity) in 254 obese non-diabetic U.S. adults across 15 sites (NCT07310901). Mean weight loss at 12 weeks: 5.0% at 60 mg (n=62), 3.3% at 40 mg (n=61), 2.8% at 20 mg (n=65) versus 0.0% on placebo (n=66) — all p<0.0001. No plateau was observed at any dose. Discontinuation rates ranged 3.1-13.1% across doses (comparable to 6.9-20.7% for oral GLP-1s in cross-trial comparison). At the 60 mg dose: nausea 22.6%, diarrhea 22.6%, constipation 4.8%, vomiting 1.6%. Psychiatric adverse events at 60 mg: depression 1.6%, anxiety 4.8%, irritability 9.7%, insomnia 0% — no serious psychiatric events or suicidality reported. CRB-913 was designed with approximately 15-fold lower brain penetration than monlunabant in preclinical models to preserve CB1-driven weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). CRBP shares closed up 12% on the day. Next steps: FDA clinical development plan engagement, Phase 2 monotherapy trial initiation in H1 2027, evaluation of a GLP-1 combination approach, and full data presentation at ObesityWeek 2026 (November 14-17, Washington DC).
Corbus Pharmaceuticals (NASDAQ: CRBP) enters Sunday September 13, 2026 the final day of the countdown to Monday September 14 at 8:00 a.m. EDT conference call disclosing Phase 1b CANYON-1 topline data for CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults across once-daily doses of 20 mg, 40 mg, and 60 mg (titrated from 20 mg over four weeks) with a 4-week safety follow-up (NCT07310901). Harold Bays MD (investigator) joins Corbus management. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off: peripheral restriction (approximately 15-fold lower brain penetration than monlunabant in preclinical models) is designed to preserve dose-responsive weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). Corbus previously reported Phase 1a mean 2.9% placebo-adjusted weight loss by Day 14. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as one of the earliest non-incretin oral obesity options alongside Novo Nordisk cagrilintide (amylin), Structure Therapeutics aleniglipron (oral small-molecule GLP-1), and the Roche petrelintide-enicepatide combo Phase 2.
Corbus Pharmaceuticals (NASDAQ: CRBP) enters the weekend before Monday September 14, 2026 at 8:00 a.m. EDT conference call disclosing Phase 1b CANYON-1 topline data for CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults across once-daily doses of 20 mg, 40 mg, and 60 mg (titrated from 20 mg) with a 4-week safety follow-up (NCT07310901). Harold Bays MD (investigator) will join Corbus management on the call. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off — the peripheral restriction (approximately 15-fold lower brain penetration than monlunabant in preclinical models) is designed to preserve dose-responsive weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as a differentiated non-incretin add-on or alternative to the GLP-1 class. Monday's readout is one of the most-watched non-GLP-1 obesity data points on the September calendar.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced Friday September 11, 2026 that the company will host a conference call and webcast Monday September 14 at 8:00 a.m. EDT to discuss topline data from the Phase 1b CANYON-1 trial of CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up (NCT07310901). Last patient last visit was reported August 4, 2026. Harold Bays MD (investigator) will join the call as a guest speaker. CRB-913 is designed to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve weight-loss efficacy while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). The Monday readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and position CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Sunday September 6, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update — the specific readout date has not been disclosed but the September window narrows with each passing day. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. Investor focus is on the CB1 inverse agonist class safety-versus-efficacy trade-off plus dose-responsive weight loss. Clean data enables Phase 2 initiation and would position CRB-913 as a non-incretin add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Saturday September 5, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Friday September 4, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. A clean tolerability profile plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Thursday September 3, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. A clean tolerability profile plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the incretin class.
Corbus Pharmaceuticals (NASDAQ: CRBP) confirmed Tuesday September 1, 2026 that the CANYON-1 Phase 1b topline data readout for CRB-913 (a once-daily orally-administered highly peripherally-restricted CB1 inverse agonist for obesity) remains on track for September 2026, following completion of the last patient last visit announced August 4. The CANYON-1 study is a 16-week double-blind placebo-controlled dose-ranging trial in 240 obese non-diabetic U.S. adults testing once-daily oral doses of 20 mg, 40 mg, and 60 mg versus placebo with dose titration and 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than the CB1 inverse agonist monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to the withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The mechanism is designed to complement or serve as an alternative to GLP-1 receptor agonists, and the CANYON-1 tolerability profile will determine whether Corbus advances CRB-913 into Phase 2 later in 2026.